mild, moderate Novel Coronavirus Infectious Disease (COVID-19) (DBCOND0134176)

Identifiers

Synonyms

Mild to Moderate COVID-19 / Mild-to-moderate COVID-19

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bamlanivimab	A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.	Spike glycoproteintarget
Etesevimab	Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...	Spike glycoproteintarget
Imdevimab	Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.	Spike glycoproteintarget
Molnupiravir	An orally bioavailable isopropylester cytidine analog used to treat COVID-19.	No drug targets
Nirmatrelvir	An oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19.	Replicase polyprotein 1abtarget Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter
Remdesivir	A nucleoside analog used to treat RNA virus infections including COVID-19.	Replicase polyprotein 1abtarget RNA-directed RNA polymerase Ltarget Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Cytochrome P450 3A4enzyme Solute carrier organic anion transporter family member 1B1transporter ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1B3transporter Bile salt export pumptransporter ATP-binding cassette sub-family C member 4transporter Hepatic sodium/bile acid cotransportertransporter Liver carboxylesterase 1enzyme Lysosomal protective proteinenzyme Replicase polyprotein 1abtarget Replicase polyprotein 1abtarget Multidrug and toxin extrusion protein 1transporter
Ritonavir	An HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection.	Pol polyproteintarget Cytochrome P450 2D6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 2transporter Solute carrier organic anion transporter family member 1A2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Cytochrome P450 1A2enzyme Nuclear receptor subfamily 1 group I member 2target Albumincarrier Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme UDP-glucuronosyltransferases (UGTs)enzyme Solute carrier organic anion transporter family member 2B1transporter Bile salt export pumptransporter Alpha-1-acid glycoprotein 1carrier Solute carrier organic anion transporter family member 1B3transporter Gag-Pol polyproteintarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05941793	A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients	No drug interventions	treatment	2	completed
NCT05242042	JT001 (VV116) for the Early Treatment of COVID-19	No drug interventions	treatment	2 / 3	terminated
NCT05582629	JT001 (VV116) for the Treatment of COVID-19	No drug interventions	treatment	3	completed
NCT05675072	Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19	No drug interventions	treatment	2 / 3	recruiting
NCT06197217	Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19	No drug interventions	treatment	3	completed
NCT04521296	Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo	No drug interventions	treatment	2 / 3	terminated
NCT04711863	Fluvoxamine for Adults With Mild to Moderate COVID-19	Fluvoxamine	treatment	2	suspended
NCT05620160	Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19	No drug interventions	treatment	3	completed
NCT04705844	Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)	Adalimumab	treatment	3	withdrawn
NCT04414124	A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19	No drug interventions	other	Not Available	completed
NCT05157139	Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease	No drug interventions	treatment	2 / 3	unknown_status
NCT04486482	A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function	No drug interventions	other	Not Available	completed